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Purpose: To develop and evaluation ascorbyl palmitate niosomes in order to achieve a transdermal 
and/or systemic nanocarier of doxycycline. 
Methods: Vesicles were formed from ascorbyl palmitate in combination with cholesterol and a 
negatively charged lipid, dicetyl phosphate. Niosomes were prepared by film hydration method followed 
by sonication in which aqueous doxycycline solution (in phosphate buffered saline) was encapsulated in 
the aqueous regions of the vesicles. The vesicles were evaluated for entrapment and in vitro release as 
well as for their thermal properties and shape by ultraviolet spectroscopy (UV), differential scanning 
calorimetry (DSC) and scanning electron microscopy (SEM), respectively.  The effect of process 
conditions - sonication time, pH, hydration temperature and centrifuge speed - on niosome properties 
was investigated. 
Results: DSC of pure lipids, vesicles dispersion and mixture of lipids confirmed the formation of 
niosomes. Other results show that > 90 % of drug was entrapped in the vesicles and the vesicles were 
spherical in shape. Drug release from the vesicles was slow (< 60 % after 8 h). Nanovesicle size was 
significantly (p < 0.05) affected by sonication time and hydration pH. Although hydration temperature of 
100 °C promoted the production of smaller vesicles, this temperature would likely cause drug 
degradation. 
Conclusion: The use of ascorbyl palmitate along with cholesterol and a charge inducer (dicetyl 
phosphate) yielded vesicles that satisfactorily encapsulated doxycycline solution. The resulting system 
can be applied for the formulation of doxycycline niosomes. 
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INTRODUCTION 
 
Tetracycline manifests a broad safety profile. 
Doxycycline requires less frequent 
administration and is considered safer than 
tetracycline [1]. Doxycycline, a semi-synthetic 
derivative of oxytetracycline is a potent 
antibacterial drug, commonly used as 
doxycycline hyclate [2]. Doxycycline is more 
active than tetracycline against many 
bacterial species including the entrococci and 
various anaerobes, protozoa and 
plasmodium. It has a broad-spectrum of 
activity against a wide variety of 
microorganisms, has been successfully used 
in man for more than 40 years and is 
commonly employed in the therapy of certain 
respiratory, skin, soft tissue and genitourinary 
infections, intestinal amoebiasis, anthrax, 
acute acne and also in the prophylaxis of 
malaria [2-3].  
 
Other actions of doxycycline include 
differential inhibition of the activity of 
members of the matrix metalloproteinase 
(MMP) family, inhibition of interleukin-1 
synthesis, inhibition of activated B cell 
function, inhibition of nitrous oxide (NO) 
synthesis by lipopolysaccharide (LPS) 
activated macrophage, and inhibition of 
collagen synthesis by cultured chondrocytes. 
With varying degrees of success it has been 
used to treat patients with rheumatoid arthritis 
[4]. It inhibits collagen synthesis and 
collagenase activity in hypertrophic 
chondrocytes, slowing the process of 
collagen turnover [5]. As with other 
tetracyclines it is remarkably tissue-irritating 
when injected, and so a prolonged release 
preparation of doxycycline can reduce this 
undesirable side effect [6].  
 
Designing new vehicles for old drugs is an 
important field of pharmaceutical research, 
since the severe collateral effects of a drug 
can reduce greatly its therapeutic benefits [7]. 
Niosomes are one of the colloidal drug 
carriers [8]. Preliminary studies indicate that 
niosomes behave in vivo like liposomes 
which are usually produced using 
phospholipids, prolonging the circulation of 
entrapped drug to alter its organ distribution 
and metabolic stability or to prolong the 
contact time of drug with the applied tissues 
in topical applications [8]. Niosome properties 
make them a versatile carrier that is suitable 
for different systemic and topical applications, 
the administration of anti-inflammatory drugs, 
non-invasive vaccines, and anticancer and 
anti-infective agents [9]. They offer several 
advantages over liposomes such as higher 
chemical stability, intrinsic skin penetration, 
and lower cost [10]. 
 
There are a few materials with amphiphilic 
moieties that are biologically active. Uchegbu 
et al have synthesized palmitoyl muramic 
acid and N-palmitoyl glucosamine to improve 
immuno- adjuvant effect and/or targeting to 
malignant tissues [11]. Niosomes are vesicles 
formed from non-ionic surfactants in the 
manner analogous to liposomes preparation. 
They are capable of entrapping small water-
soluble solutes within an aqueous core and 
they have been proposed as possible 
alternatives to liposomes in drug delivery and 
targeting [12].  
 
Ascorbic acid esters are amphiphilic and 
delineating studies about their surface active 
properties and applications have been 
reported [13-14]. Ascorbyl palmitate (AP) is 
an antioxidant used in both cosmetics and 
food industry. It has been shown that this 
material can protect human erythrocytes from 
oxidative damage [15].  
 
The aim of this paper was to encapsulate 
sufficient quantities of doxycycline in vesicles 
made with ascorbyl palmitate and to evaluate 
the resulting niosomes as possible 







Ascorbyl acid-6-palmitate, dicetyl phosphate, 
doxycycline hydrocholoride, and dialysis 
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tubing (cellulose membrane, 12400 Mw cut-
off) were obtained from Sigma Aldrich 
Chemical Company, Germany. Cholesterol 
was obtained from Applichem, Germany 
while chloroform and methanol (analytical 
grade) were purchased from Merck, Germany  
 
Preparation of vesicles 
 
A lipid mixture of ascorbyl palmitate (AP, 200 
µ mol) and cholesterol (Ch) in varying molar 
ratios plus 10 mol % of dicetyl phosphate 
(DCP)) was dissolved in 9 ml chloroform and 
1 ml of methanol in a round bottom flask 
under nitrogen atmosphere. The solvent was 
evaporated under reduced pressure at 50 ºC. 
The lipid film was dried in an evaporator and 
then hydrated with 10 ml of phosphate 
buffered saline (PBS, pH=7.4) containing 
doxycycline (2 mg/ml) maintained at the 
same temperature. The vesicles were 
sonicated for varying times, using an 
ultrasonicator (Citizen SW 1500, India). 
Formation of vesicles was confirmed by SEM 
photographs as well as observation of 
unsonicated vesicles by light microscope 
(Zeiss, Germany). The vesicles were stored 
in nitrogen-purged vials at room temperature. 
 
Characterization of vesicles 
 





The encapsulation efficiency of the niosome 
formulations were determined by 
centrifugation of 5 ml samples at 24000 rpm 
for 15 min (high speed centrifuge, Hermle 
236 HK, Germany). Supernatant doxycycline 
concentration was assessed by UV-Vis 
spectrophotometer (V 630, Jasco, Japan) at 
λmax of 265 nm. The size of any particles in 
the supernatant was measured to ensure no 
vesicles were remained in the supernatant.  
Phosphate buffered saline (PBS, pH = 7.4) 
was used as blank and all measurements 
were performed in triplicate. Doxycycline 
entrapment efficiency (DE) was calculated as 
in Eq 1. 
 
DE = 100(TD - FD)/TD  ………………….... (1) 
 
where TD is the total doxycycline used in the 
preparation of the vesicles and FD is the 
doxycycline content of the supernatant 
 
Assessment of size, characteristics and zeta 
potential of vesicles 
 
The size, size distribution and zeta potential 
of the vesicles were determined by zetasizer 
nanoparticle analyser (Zetasizer 3600, 
Malvern instruments, UK) at 25 °C and a 
scattering angle of 90°.  
  
Differential scanning calorimetry (DSC) of 
vesicles 
 
Both the vesicle dispersion and anhydrous 
mixture of AP/Ch/DCP were studied by DSC 
method (Perkin Elmer, Germany) to 
understand the thermotropic properties and 
phase transition behaviour of the vesicles. 
Analysis was carried out in a conventional 
aluminium pan. The pans covered with 
aluminium lid, sealed and perforated, and 
then heated from 50 to 250 °C at 10 °C/min. 
An empty loosely covered aluminium pan 
was used as the reference.  
 
Evaluation of in vitro doxycycline release 
 
The vesicles were collected after 
centrifugation of samples at 10000 rpm for 20 
min (Hermle 236 HK, Germany). The 
supernatant solutions were used for in vitro 
doxycycline release study. In vitro release 
was determined using a vertical diffusion cell. 
Prior to the release study, extent smuch of 
the unentrapped doxycycline was removed 
by dialyzing the samples in PBS (pH=7.4) for 
one hour. Four millilitres of dialyzed vesicle 
preparation was subjected to release studies. 
The receptor cell was filled with PBS. 
Dialyzed vesicles or doxycycline solution (in 
PBS, pH = 7.4) was transferred to the donor 
cell (5 ml capacity). Three ml samples were 
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withdrawn from the receptor cell at various 
intervals over a period of 24 h. The withdrawn 
sample was replenished with an equivalent 
volume of PBS. The samples were analyzed 
spectrophotometrically at 265 nm.  
 
Scanning electron microscopy of the vesicles 
(SEM) 
 
A scanning electron microscope (model 2360 
Leo Oxford, England) was used to analyze 
the surface and shape characteristics of the 




The results were expressed as mean ± SD. 
Student’s t-test and one-way analysis of 
variance (ANOVA) were applied to check 
significant differences in drug release from 
different formulations. Differences were 
considered to be statistically significant at p < 
0.05. Sigma Plot 5 was used as the software 
for the analysis. 
 
RESULTS   
 
Ascorbyl palmitate and cholesterol, in the 
presence of dicetyl phosphate, a negatively 
charged lipid, formed stable spherical 
vesicles. Formation of vesicles was 
confirmed by SEM photographs of the 
vesicles as Fig 1) as well as observation of 
unsonicated vesicles by light microscopy 
(450 x and 1500 × magnification).  
 
Effect of various process parameters on 
nanovesicle properties 
 
The effect of composition of the lipid 
materials on vesicles size, zeta potential and 
entrapment efficiency of doxycycline is shown 
in Table 1. The properties of the doxycycline 
nanovesicles were affected by process 
conditions. The size of doxycycline vesicles 
significantly decreased (p < 0.05) from 304 
nm (F1) to 185 nm (F7) when the rate of 
ultracentrifuge increased from 5000 to 23000 
RPM. The results also show that increasing 
the temperature from 50 to 70°C in the 





Figure 1:  Scanning electron microphotographs of 
F5 niosomes 
 
Although hydration temperature of 100 °C 
produced smaller vesicles, this temperature 
is high and could cause drug degradation.  
 
The results (Fig 2) show that the size of the 
nanovesicles significantly decreased (p < 
0.05) from 275 nm (F8) to 183 nm (F10) and 
the vesicle size became more uniform when 
the sonication time was increased from 2 to 
20 min. Another factor is the hydration pH of 
the solution. Although decreasing the pH of 
hydration from 7.4 to 7 and 6.8 produced no 
significant difference in vesicle size, increase 





Fig 2: The size and size distribution profiles of 
vesicles obtained without sonication ( __ ), with 
sonication for 2 min (…..), and sonication for 20 




DSC scans of anhydrous mixtures of lipid 
mixture in varying proportios nks could be 
related to dehydration, melting and  
Honary & Zahir  
Trop J Pharm Res, April 2012;11 (2): 173 
Table 1:  The effect of different conditions on doxycycline vesicle 
Key: pH= hydration pH; Temp = hydration temperature; RPM = centrifuge speed; Time = sonication time; Mean size  = 




Fig 3:  Differential scanning calorimetry (DSC) 
scans. (A) different AP, Ch and DCP mixture: 
45:45:10 (        ), 36:54:10 (        ), and 27:63:10  
(     ). (B) pure doxycycline (    ), doxycycline 
vesicles (         )   
 
decomposition of docycycline, respectively 
(Fig. 3B). Doxycycline vesicle dispersion in 
PBS (Fig 3B) showed one main exothermic 
peak at 120 ºC followed by an endothermic 
peak at 140 ºC. Table 1 shows that variation 
in processing conditions did not show 
significant effect (p < 0.05) on entrapment 
and zeta potential of the vesicles 
 
 
Fig 4: In vitro release profiles of doxycycline from 
vesicles (♦) and doxycycline solution (□) 
 
Fig 4 shows that the the release of drug from 
doxycycline vesicles was significantly slower 
(p < 0.05) than from the drug solution.  
 


















F1 45%Ap:45%Ch:10%Dp 7.4 50 5000 2 304 90 -37 
F2 45%Ap:45%Ch:10%Dp 7.4 50 10000 2 250 92 -37 
F3 45%Ap:45%Ch:10%Dp 7.4 50 15000 2 235 91 -37 
F4 45%Ap:45%Ch:10%Dp 7.4 50 20000 2 210 91.5 -37 
F5 45%Ap:45%Ch:10%Dp 7.4 50 23000 2 185 90.5 -38 
F6 45%Ap:45%Ch:10%Dp 7.4 70 10000 2 280 92 -37 
F7 45%Ap:45%Ch:10%Dp 7.4 100 10000 2 227 91.5 -37 
F8 45%Ap:45%Ch:10%Dp 7.4 50 10000 - 275 92 -38 
F9 45%Ap:45%Ch:10%Dp 7.4 50 10000 10 204 91 -37 
F10 45%Ap:45%Ch:10%Dp 7.4 50 10000 20 183 90.5 -37 
F11 45%Ap:45%Ch:10%Dp 7.4 50 - 40 580 94 -37 
F12 45%Ap:45%Ch:10%Dp 7.4 50 - 60 390 93 -37 
F13 45%Ap:45%Ch:10%Dp 6.8 50 10000 2 248 90.8 -38 
F14 45%Ap:45%Ch:10%Dp 7 50 10000 2 246 91.5 -38 
F15 45%Ap:45%Ch:10%Dp 7.7 50 10000 2 219 92 -39 
F16 45%Ap:45%Ch:10%Dp 8 50 10000 2 222 91 -39 
F17 36%Ap:54%Ch:10%Dp 7.4 50 10000 2 432 94 -38 
F18 27%Ap:63%Ch:10%Dp 7.4 50 10000 2 325 93 -38 
F19 45%Ap:45%Ch:10%Dp 7.7 70 15000 20 181 91.5 -39 
A B 
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DISCUSSION 
 
Based on the results obtained, the most 
important factor that influenced the size of the 
vesicles is the sonication time. Increasing 
ultra-sonication time to 20 min yielded more 
uniform and smaller vesicles. For example, 
the size of 5-Fu niosomes decreased from 
500 to 200 nm using this method. However, 
sonication of 5-Fu-loaded niosomes elicited a 
slight reduction of carrier capacity [9]. In the 
present work, sonication time had no 
significant effect on the entrapment efficiency 
of the vesicles. 
 
Previously reported DSC scans of AP, Ch 
and DCP showed melting endotherms at 116, 
149 and 82 ºC, respectively [16]. DSC scans 
of various anhydrous fatty mixtures (AP, Ch 
and DCP) are shown in Fig.3A. The first peak 
is due to simple melting of eutectic mixture 
and this was followed by three other peaks; 
the first two peaks could related to 
mesospheric transition, or may be smectic or 
cholestric phases. It was shown earlier [16] 
that with increase in Ch concentration in lipid 
mixture, an increase in the area of the fourth 
peak was observed which could be related to 
pure Ch. Increase in Ch concentration slightly 
decreased the main transition temperature. 
The liquid crystalline state is a prerequisite 
for the formation of vesicles[16]. The DSC 
results show evidence for the formation of 
liquid crystals with ascorbyl palmitate, 
cholesterol and DCP anhydrous mixture. The 
DSC thermogram of doxycycline pure powder 
shows two sharp endothermic peaks at 155 
and 205 ºC, which was followed an 
exothermic peak at 230 ºC. These peaks may 
be related to dehydration melting point and 
decomposition of docycycline at these 
temperatures, respectively. The vesicle 
dispersion of doxycicline in PBS (Fig 3B) 
showed one main exothermic peak at 120 ºC, 
followed by an endothermic peak at 140 ºC. 
This thermogram shows major differences 
from that of the pure doxycycline. Thus, the 
thermograms suggest vesicle formation and 
drug loading.   
 
Flurbiprofen entrapment efficiency increased 
at acidic pH condition [10]. Decreasing pH 
could increase the proportion of the unionized 
species of an acidic drug, such as 
flurbiprofen,, which have higher partitioning to 
the bilayer lipid phase compared to the 
ionized species. However, a drug model such 
as doxycycline with different dissociation 
constants (3.5, 7.7 and 9.5) could show 
completely different results. The results 
demonstrated that changing pH in the range, 
6.8 to 8 did not have significant effect on the 
size and entrapment of vesicles (table 1). 
Although increasing hydration temperature 
from 50 to 100 ⁰C yielded smaller vesicles, it 
is not applicable owing to drug instability in 
high temperature. More than 90 % of drug 
was entrapped in the vesicles in all 
formulations.  
 
The zeta potential of formulations varied from 
-37 to -39 mV. The stability of emulsion and 
colloids, according to DLVO electrostatic 
theory, is a balance between the attractive 
“Van der Waals” forces and the electrical 
repulsion because of the net surface charge. 
If the zeta potential falls below a certain level, 
the emulsion droplets or colloids will 
aggregate as a result of the attractive forces. 
Conversely, a high zeta potential (either 
positive or negative), typically more than 30 
mV, maintains a stable system [16]. 
 
In this kind of vesicles, polar ascorbyl head 
groups would project out of the vesicle 
surface, whereas palmitate chains would 
aggregate due to hydrophobic interaction. 
Overall, the free polar ascorbyl head groups, 
hydrophobicity/amphiphilicity and nanosize of 
this vesicle might enable it to neutralize 
reactive oxygen species of blood as well as 
produce much higher adhesion to 
biomembrans which might allow them to 





Ascorbyl palmitate formed vesicles in 
presence of cholesterol and charge inducer 
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dicetyl phosphate, encapsulating Doxycycline 
solution. This system could be employed as a 
drug delivery system for the formulation of 
doxycycline niosomes. Vesicles were 
spherical and released their content slower 
than doxycycline solution. This technique 
reported may be useful in the production of 
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